Nuvalent, Inc.
About Nuvalent, Inc.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of its operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
American Credentials
Each credential is independently reviewed before it’s awarded · last reviewed Jun 9, 2026. How this is verified →
Financial summary
- Net income
- -$425.4M
- Total assets
- $1.4B
- Market cap
- $7.2B
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $414.3M
- Operating income
- -$414.3M
- Income tax
- $585.0K
- Net income
- -$425.4M
- EPS (basic)
- $-5.85
- EPS (diluted)
- $-5.85
Balance sheet
- Total assets
- $1.4B
- Current assets
- $1.4B
- Total liabilities
- $164.4M
- Current liabilities
- $91.2M
- Shareholders’ equity
- $1.2B
Cash flow
- Operating cash flow
- -$275.2M
- Investing cash flow
- -$124.1M
- Financing cash flow
- $515.3M
- Net cash flow
- $116.1M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $7.2B
- EPS (diluted)
- $-5.85
- Shares outstanding
- 81.2M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jul 29, 2021
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $425.4M.
- Trading 21% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Nuvalent, Inc..
Write a review
News about Nuvalent, Inc.
News & sentiment via Polygon.io
